Because of the clinics discharge policy, at the end of my appointment I was required to be given intramuscular self-injection training by my doctors nurse
Oral BPC-157 for Gastrointestinal Conditions Injectable BPC-157 for Musculoskeletal Conditions Injection Technique and Patient Education All patients receiving injectable BPC-157 are provided with: Detailed written instructions for reconstitution, storage, and administration In-person or video training on proper subcutaneous injection technique Sharps disposal containers and guidance on safe disposal 24-hour clinical contact for questions or concerns Most patients self-administer injections after the first week of supervised dosing

Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Research note: A 2025 literature and patent review catalogued BPC-157's multifunctional activity across gastrointestinal, musculoskeletal, neurological, and cardiovascular preclinical models
Nothing I've read or the neurologist I saw read has convinced me oral b12 works as well for most people with PA or another absorbtion problem